Shahar Shelly | Epidemiology | Best Researcher Award Posted on 29/11/202430/11/2024 by sciencefather Dr. Shahar Shelly | Epidemiology | Best Researcher Award Dr. Shahar Shelly, Rambam Medical Center, Israel. Dr. Shahar Shelly, MD, is a globally recognized neurologist and researcher specializing in neuroimmunology and neuromuscular disorders. With academic roles across Rambam Medical Center, Technion Institute, and the Mayo Clinic, Dr. Shelly has driven advancements in clinical diagnostics, treatment strategies, and disease understanding. profile Scholor 🎓 Education University Medical School of Hungary, Debrecen – Summa Cum Laude (01/2005–01/2012). Shamir Medical Center, Zerifin, Israel – Internship (Cum Laude) (01/2012–01/2013). Sheba Medical Center – Residency, Neurology Department (01/2013–01/2017). Mayo Clinic, Rochester, MN – Neuroimmunology Fellowship (04/2018–07/2019). Neuromuscular Disorders, Muscle Fellowship – Mayo Clinic (07/2019–07/2020) Neuromuscular Disorders, Nerve Fellowship – Mayo Clinic (07/2020–07/2021). 📜 Certifications Israeli Neurology Board Certification (2018). Educational Commission for Foreign Medical Graduates (ECFMG) (2018). Mayo Clinic Quality Fellow Certification (2019). Medical Genetics Certificate – Recanti Genetic Institute (2015). Advanced Electrophysiology Certification – Board-Licensed Electromyography (2019). 🏆 Honors & Awards Summa Cum Laude – University Medical School of Hungary. Cum Laude – Hassaf Harofeh Medical Center Internship.Israel Medical Association Fellowship Award (2017). Best Abstract Award – American Academy of Neurology (2019). 🔬 Patents & Innovations Digital Drug Amplifier – Combines digital therapeutics with pharmaceuticals (FDA-approved). IMNM Muscle Disease Screening Software – Released for public use in the USA (2020). 🌐 Professional Memberships American Neurological Association.Israeli Neuromuscular Society.American Association of Neuromuscular & Electrodiagnostic Medicine 📚 Publications Prolactin and autoimmunity Authors: S Shelly, M Boaz, H Orbach Year: 2012 Autonomic dysfunction following COVID-19 infection: an early experience Authors: K Shouman, G Vanichkachorn, WP Cheshire, MD Suarez, S Shelly, et al. Year: 2021 Thymoma and autoimmunity Authors: S Shelly, N Agmon-Levin, A Altman, Y Shoenfeld Year: 2011 Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy Authors: S Shelly, JD Triplett, MV Pinto, M Milone, FE Diehn, A Zekeridou, et al. Year: 2020 Epidemiology and natural history of inclusion body myositis: a 40-year population-based study Authors: S Shelly, MM Mielke, J Mandrekar, M Milone, FC Ernste, E Naddaf, et al. Year: 2021 Survival and associated comorbidities in inclusion body myositis Authors: E Naddaf, S Shelly, J Mandrekar, AM Chamberlain, EM Hoffman, et al. Year: 2022 Small fiber neuropathy incidence, prevalence, longitudinal impairments, and disability Authors: SA Johnson, K Shouman, S Shelly, P Sandroni, SE Berini, PJB Dyck, et al. Year: 2021 Neurochondrin neurological autoimmunity Authors: S Shelly, TJ Kryzer, L Komorowski, R Miske, MD Anderson, EP Flanagan, et al. Year: 2019 Potential neurotoxicity of titanium implants: Prospective, in-vivo and in-vitro study Authors: S Shelly, SL Zaltsman, O Ben-Gal, A Dayan, I Ganmore, C Shemesh, et al. Year: 2021 Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes Authors: S Shelly, CJ Klein, PJB Dyck, P Paul, ML Mauermann, SE Berini, B Howe, et al. Year: 2021 Conclusion Dr. Shahar Shelly exemplifies excellence in clinical practice, academic leadership, and innovative research. His focus on using cutting-edge technologies like AI and biomarker discovery aims to transform the diagnosis and treatment of complex neurological and neuromuscular disorders. Driven by a commitment to precision medicine, his career reflects a blend of academic rigor, clinical expertise, and groundbreaking contributions that continue to shape the future of neurology.
📚 Publications Prolactin and autoimmunity Authors: S Shelly, M Boaz, H Orbach Year: 2012 Autonomic dysfunction following COVID-19 infection: an early experience Authors: K Shouman, G Vanichkachorn, WP Cheshire, MD Suarez, S Shelly, et al. Year: 2021 Thymoma and autoimmunity Authors: S Shelly, N Agmon-Levin, A Altman, Y Shoenfeld Year: 2011 Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy Authors: S Shelly, JD Triplett, MV Pinto, M Milone, FE Diehn, A Zekeridou, et al. Year: 2020 Epidemiology and natural history of inclusion body myositis: a 40-year population-based study Authors: S Shelly, MM Mielke, J Mandrekar, M Milone, FC Ernste, E Naddaf, et al. Year: 2021 Survival and associated comorbidities in inclusion body myositis Authors: E Naddaf, S Shelly, J Mandrekar, AM Chamberlain, EM Hoffman, et al. Year: 2022 Small fiber neuropathy incidence, prevalence, longitudinal impairments, and disability Authors: SA Johnson, K Shouman, S Shelly, P Sandroni, SE Berini, PJB Dyck, et al. Year: 2021 Neurochondrin neurological autoimmunity Authors: S Shelly, TJ Kryzer, L Komorowski, R Miske, MD Anderson, EP Flanagan, et al. Year: 2019 Potential neurotoxicity of titanium implants: Prospective, in-vivo and in-vitro study Authors: S Shelly, SL Zaltsman, O Ben-Gal, A Dayan, I Ganmore, C Shemesh, et al. Year: 2021 Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes Authors: S Shelly, CJ Klein, PJB Dyck, P Paul, ML Mauermann, SE Berini, B Howe, et al. Year: 2021
Conclusion Dr. Shahar Shelly exemplifies excellence in clinical practice, academic leadership, and innovative research. His focus on using cutting-edge technologies like AI and biomarker discovery aims to transform the diagnosis and treatment of complex neurological and neuromuscular disorders. Driven by a commitment to precision medicine, his career reflects a blend of academic rigor, clinical expertise, and groundbreaking contributions that continue to shape the future of neurology.